secwatch.observer — SEC 8-K summary
======================================

Issuer:     QUEST DIAGNOSTICS INC (DGX)
CIK:        0001022079
Form:       8-K
Filed at:   2022-01-12T23:59:59+00:00
Accession:  0001022079-22-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quest Diagnostics Q4 rev $2.74B (-9% YoY); FY EPS beats outlook; 2022 guidance raised
--------------------------------------------------------------------------------

- Preliminary Q4 2021 revenue ~$2.74B, down 9% from $3.00B in Q4 2020.
- Q4 reported diluted EPS $3.12; adjusted diluted EPS $3.33 (vs $4.48 adjusted in Q4 2020).
- Full year 2021 revenue ~$10.79B (+14% YoY); adjusted diluted EPS $14.24 exceeded prior outlook.
- COVID-19 testing demand higher than expected; Q4 included 7.9M molecular tests and 0.7M serology tests.
- 2022 guidance raised: now expects adjusted diluted EPS above $8.00 (prior was near upper end of $7.40-$8.00).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022079/000102207922000005/0001022079-22-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022079/000102207922000005/dgx-20220112.htm
  HTML page:      https://secwatch.observer/filing/0001022079-22-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer